(1 - 13 von 13
)
New Sandoz biosimilar adalimumab data confirms switching from...
www.myscience.ch
LinkedIn · Facebook · Twitter · WhatsApp Web · Email ... to a biosimilar", adds Dr. Marc Schmalzing, Deputy Head Rheumatology and Immunology at University ...
New Sandoz biosimilar adalimumab data confirms Novartiswww.novartis.com › news › media-releases › new-sa...
www.novartis.com
· Marc Schmalzing, Deputy Head Rheumatology and Immunology at University Hospital Würzburg. In 2018, Hyrimoz® was approved for use and ...
sortiert nach Relevanz / Datum